AbbVie Announces Michael Severino, M.D. to Lead R&D Organization

16-May-2014 - USA

AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline .

Dr. Severino's responsibilities include leading the R&D, Medical Affairs and Regulatory Affairs organizations at AbbVie. Globally, AbbVie has more than 7,000 people in the collective scientific organization dedicated to discovering and developing a steady stream of new medicines for patients. Severino will bring insights and expertise from his career spanning genomics and development within the biotech industry.

At Amgen, Dr. Severino most recently served as Senior Vice President and Chief Medical Officer, leading the clinical development strategy across therapeutic areas including inflammation/immunology, neuroscience, oncology and cardiovascular disease, among others. In his 10 years with the company, he held numerous roles of increasing responsibility across the R&D organization. Prior to his tenure at Amgen, Dr. Severino held increasing levels of responsibility in biologics and genomics research at Merck.

Other news from the department people

More news from our other portals

All FT-IR spectrometer manufacturers at a glance